公开(公告)号：US20170043178A1

公开(公告)日：2017-02-16

申请号：US15247367

申请日：2016-08-25

Applicant: IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

Inventor： Tuan VO-DINH ,  Jonathan P. SCAFFIDI ,  Venkata Gopal Reddy CHADA ,  Benoit LAULY ,  Yan ZHANG ,  Molly K. GREGAS ,  Ian Nicholas STANTON ,  Joshua T. STECHER ,  Michael J. THERIEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zak FATHI ,  Jennifer A. AYRES ,  Zhenyuan ZHANG ,  Joseph H. SIMMONS ,  Stephen John NORTON

IPC: A61N5/06 ,  A61N5/10 ,  A61L2/00 ,  A61B5/055 ,  A61B6/00 ,  A61K41/00 ,  A61M5/00 ,  A61B5/00

CPC classification number: A61N5/062 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/055 ,  A61B5/4848 ,  A61B6/481 ,  A61K41/0042 ,  A61K41/0052 ,  A61K41/0061 ,  A61K49/0039 ,  A61L2/0047 ,  A61L2/08 ,  A61L2202/21 ,  A61L2202/22 ,  A61M5/007 ,  A61N1/406 ,  A61N5/02 ,  A61N5/0601 ,  A61N5/0618 ,  A61N5/0622 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/063 ,  A61N2005/0656 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  A61N2005/1098

Abstract: Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

Abstract translation: 用于修饰介导或与生物活性相关的靶结构的产物，组合物，系统和方法，包括治疗由病毒，细胞，亚细胞结构介导或与靶结构相关的疾病，病症或疾病 或胞外结构。 所述方法可以以非侵入性方式在原位进行，通过将具有金属壳的纳米颗粒放置在受试者的靶结构附近的表面的至少一部分上，并向受试者施加引发能量，从而产生 直接或通过调制剂对目标结构的影响或改变。 纳米颗粒在暴露于第一波长λ1时被配置为产生具有比第一波长λ1更高的能量的辐射的第二波长λ2。 所述方法还可以通过向受试者原位施加引发能量来直接或经由能量调节剂活化药剂，任选地在一种或多种等离子体激活剂活性剂的存在下进行，从而产生对其的作用或改变 目标结构。 包含配制或配置的产品或组合的套件以及用于实施这些方法的系统。

公开(公告)号：US20170000908A1

公开(公告)日：2017-01-05

申请号：US15100270

申请日：2014-11-27

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Xu LI ,  Changliang REN ,  Yu ZHANG ,  John WANG

IPC: A61K49/00 ,  A61K9/51

CPC classification number: A61K49/0093 ,  A61K9/5115 ,  A61K49/0021 ,  A61K49/0039 ,  B82Y5/00 ,  B82Y30/00 ,  C09K11/02 ,  C09K11/06 ,  Y10S977/906 ,  Y10S977/927

Abstract: There is provided a micellar particle having at least a core-shell configuration, wherein a fluorescent molecule is encapsulated within said core and wherein said shell is formed from an inorganic compound.

Abstract translation: 提供了至少具有核 - 壳构型的胶束颗粒，其中荧光分子被包封在所述芯内，并且其中所述壳由无机化合物形成。

公开(公告)号：US09526914B2

公开(公告)日：2016-12-27

申请号：US14716394

申请日：2015-05-19

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Tuan Vo-Dinh ,  Jonathan P. Scaffidi ,  Venkata Gopal Reddy Chada ,  Benoit Lauly ,  Yan Zhang ,  Molly K. Gregas ,  Ian Nicholas Stanton ,  Joshua T. Stecher ,  Michael J. Therien ,  Frederic A. Bourke, Jr. ,  Harold Walder ,  Zak Fathi ,  Jennifer A. Ayres ,  Zhenyuan Zhang ,  Joseph H. Simmons ,  Stephen John Norton

IPC: A61B5/00 ,  A61N5/06 ,  A61K49/00 ,  A61L2/08 ,  A61N1/40 ,  A61N5/02

CPC classification number: A61N5/062 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/055 ,  A61B5/4848 ,  A61B6/481 ,  A61K41/0042 ,  A61K41/0052 ,  A61K41/0061 ,  A61K49/0039 ,  A61L2/0047 ,  A61L2/08 ,  A61L2202/21 ,  A61L2202/22 ,  A61M5/007 ,  A61N1/406 ,  A61N5/02 ,  A61N5/0601 ,  A61N5/0618 ,  A61N5/0622 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/063 ,  A61N2005/0656 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  A61N2005/1098

Abstract: Products, compositions, systems, and methods for modifying a target structure. The methods may be performed in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to activate a photoactivatable agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure.

Abstract translation: 用于修改目标结构的产品，组成，系统和方法。 所述方法可以以非侵入性方式进行，通过将具有金属壳的纳米颗粒放置在受试者的靶结构附近的表面的至少一部分上，并施加引发能量，从而产生作用或改变 目标结构直接或通过调制剂。 纳米颗粒在暴露于第一波长λ1时被配置为产生具有比第一波长λ1更高的能量的辐射的第二波长λ2。 所述方法还可以通过施加起始能量来直接地或经由能量调节剂，任选地在一种或多种等离子体激元活性剂的存在下活化可光活化剂，从而对目标结构产生影响或改变。

公开(公告)号：US20160361442A1

公开(公告)日：2016-12-15

申请号：US15244835

申请日：2016-08-23

Applicant: CANON KABUSHIKI KAISHA

Inventor： Kohei Watanabe ,  Taichi Shintou ,  Tsuyoshi Nomoto ,  Takeshi Miyazaki ,  Mie Okano ,  Toshio Tanaka ,  Yuhei Nishimura ,  Yasuhito Shimada

IPC: A61K49/00

CPC classification number: A61K49/0032 ,  A61K49/0039 ,  A61K49/006 ,  C07D417/06 ,  G01N33/50 ,  G01N33/58 ,  G01T1/161

Abstract: To provide a central nervous system tissue-labeling composition labeling the central nervous tissue system. Also, another object of the present invention is to provide a method for non-invasively labeling the central nervous tissue system. Further, another object of the present invention is to provide a screening method using the above central nervous system tissue-labeling composition. A central nervous system tissue-labeling composition containing, as an active ingredient, at least one of compounds represented by the general formula (1) or (7).

公开(公告)号：US09518038B2

公开(公告)日：2016-12-13

申请号：US14431707

申请日：2013-09-25

Applicant: SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY, INC.

Inventor： Guoying Zhang ,  Ying Zhang ,  Benhao Wu ,  Guohua Zhang

IPC: A01N43/16 ,  A61K31/355 ,  A61K9/127 ,  C07D311/12 ,  C07C237/06 ,  A61K31/223 ,  A61K31/37 ,  C07D311/74 ,  C07C229/22

CPC classification number: C07D311/12 ,  A61K31/223 ,  A61K31/37 ,  A61K49/0039 ,  C07B2200/07 ,  C07C229/22 ,  C07C237/06 ,  C07D311/74

Abstract: The present invention relates to a compound as represented by formula (I), which is a condensation product of a theanine derivative and a carboxylic acid coumarin derivative, compounds as represented by formula (II) and formula (III), both of which are intermediates of the condensation product, a method for preparing these compounds, a pharmaceutical composition comprising the compounds, and a use thereof in preparing a medicament for prevention and treatment of tumors, inflammation, cardiovascular diseases, immune deficiency diseases and the like. Wherein, (Ia)R═CH3R1═HR2═H (Ib)R═CH2CH3R1═HR2═H (Ic)R═CH2CH3R1═ClR2═H (Id)R═CH2CH3R1═BrR2═H (Ie)R═CH2CH3R1═FR2═H (If)R═CH2CH3R1═NO2R2═H (Ig)R═CH2CH3R1═ClR2═Cl (Ih)R═CH2CH3R1═BrR2═Br (Ii)R═CH2CH3R1═NH2R2═H Wherein, (IIa)R═CH3 (IIb)R═CH2CH3 Wherein, (IIIc)R1═ClR2═H (IIId)R1═BrR2═H (IIIe)R1═FR2═H (IIIf)R1═NO2R2═H (IIIg)R1═ClR2═Cl (IIIh)R1═BrR2═Br

Abstract translation: 本发明涉及由式（I）表示的化合物，其是茶氨酸衍生物和羧酸香豆素衍生物的缩合产物，由式（II）和式（III）表示的化合物，它们都是中间体 的缩合产物，制备这些化合物的方法，包含该化合物的药物组合物及其在制备用于预防和治疗肿瘤，炎症，心血管疾病，免疫缺陷疾病等的药物中的用途。 其中，其中，其中

公开(公告)号：US20160338962A1

公开(公告)日：2016-11-24

申请号：US15228686

申请日：2016-08-04

Applicant: Edward Turos ,  Raphael Labruere ,  Ryan Scott Cormier ,  Renaud Sicard

Inventor： Edward Turos ,  Raphael Labruere ,  Ryan Scott Cormier ,  Renaud Sicard

IPC: A61K9/14

CPC classification number: A61K9/146 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/5138 ,  A61K47/10 ,  A61K47/6933 ,  A61K49/0039 ,  A61K49/0043 ,  A61K49/0093

Abstract: The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC50>1000 μg/mL) and primary bovine primary aortic endothelial cells (IC50>500 μg/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC>250 μg/mL). Poly(vinyl benzoate) nanoparticles are suitable carriers for molecular delivery of lipophilic small molecules such as drugs pharmaceutical and imaging agents.

Abstract translation: 本发明包括作为分子载体的聚（苯甲酸乙烯酯）纳米颗粒悬浮液。 这些纳米颗粒可以通过使用Pluronic F68作为表面活性剂在水中的聚（乙烯基苯甲酸酯）的纳米沉淀形成，以产生直径约200-250nm的球形纳米结构，其在磷酸盐缓冲液和血清中是稳定的，并且在存在下仅缓慢降解 的酯酶。 在磷酸盐缓冲液中的动力学实验表明，78％的香豆素-6被包封在纳米颗粒的聚合物基质内，剩余的22％的香豆素-6被表面结合并迅速释放。 纳米颗粒在体外对人上皮细胞（IC50>1000μg/ mL）和原代牛主动脉内皮细胞（IC50>500μg/ mL）无毒性，并且对代表性测试微生物的选择施加不可观察的杀菌活性 （MIC>250μg/ mL）。 聚（苯甲酸乙烯酯）纳米颗粒是分子递送亲脂性小分子如药物药物和成像剂的合适的载体。

公开(公告)号：US20150251016A1

公开(公告)日：2015-09-10

申请号：US14716394

申请日：2015-05-19

Applicant: IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

Inventor： Tuan VO-DINH ,  Jonathan P. SCAFFIDI ,  Venkata Gopal Reddy CHADA ,  Benoit LAULY ,  Yan ZHANG ,  Molly K. GREGAS ,  Ian Nicholas STANTON ,  Joshua T. STECHER ,  Michael J. THERIEN ,  Frederic A. BOURKE, JR. ,  Harold WALDER ,  Zak FATHI ,  Jennifer A. AYRES ,  Zhenyuan ZHANG ,  Joseph H. SIMMONS ,  Stephen John NORTON

IPC: A61N5/06

CPC classification number: A61N5/062 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/055 ,  A61B5/4848 ,  A61B6/481 ,  A61K41/0042 ,  A61K41/0052 ,  A61K41/0061 ,  A61K49/0039 ,  A61L2/0047 ,  A61L2/08 ,  A61L2202/21 ,  A61L2202/22 ,  A61M5/007 ,  A61N1/406 ,  A61N5/02 ,  A61N5/0601 ,  A61N5/0618 ,  A61N5/0622 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/063 ,  A61N2005/0656 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  A61N2005/1098

Abstract: Products, compositions, systems, and methods for modifying a target structure. The methods may be performed in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to activate a photoactivatable agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

Abstract translation: 用于修改目标结构的产品，组成，系统和方法。 所述方法可以以非侵入性方式进行，通过将具有金属壳的纳米颗粒放置在受试者的靶结构附近的表面的至少一部分上，并施加引发能量，从而产生作用或改变 目标结构直接或通过调制剂。 纳米颗粒在暴露于第一波长λ1时被配置为产生具有比第一波长λ1更高的能量的辐射的第二波长λ2。 所述方法还可以通过施加起始能量来直接地或经由能量调节剂，任选地在一种或多种等离子体激元活性剂的存在下活化可光活化剂，从而对目标结构产生影响或改变。 包含配制或配置的产品或组合的套件以及用于实施这些方法的系统。

公开(公告)号：US20150239861A1

公开(公告)日：2015-08-27

申请号：US14431707

申请日：2013-09-25

Applicant: SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY, INC.

Inventor： Guoying Zhang ,  Ying Zhang ,  Benhao Wu ,  Guohua Zhang

IPC: C07D311/12 ,  C07C237/06

CPC classification number: C07D311/12 ,  A61K31/223 ,  A61K31/37 ,  A61K49/0039 ,  C07B2200/07 ,  C07C229/22 ,  C07C237/06 ,  C07D311/74

Abstract: The present invention relates to a compound as represented by formula (I), which is a condensation product of a theanine derivative and a carboxylic acid coumarin derivative, compounds as represented by formula (II) and formula (III), both of which are intermediates of the condensation product, a method for preparing these compounds, a pharmaceutical composition comprising the compounds, and a use thereof in preparing a medicament for prevention and treatment of tumors, inflammation, cardiovascular diseases, immune deficiency diseases and the like. Wherein, (Ia)R═CH3R1═HR2═H (Ib)R═CH2CH3R1═HR2═H (Ic)R═CH2CH3R1═ClR2═H (Id)R═CH2CH3R1═BrR2═H (Ie)R═CH2CH3R1═FR2═H (If)R═CH2CH3R1═NO2R2═H (Ig)R═CH2CH3R1═ClR2═Cl (Ih)R═CH2CH3R1═BrR2═Br (Ii)R═CH2CH3R1═NH2R2═H Wherein, (IIa)R═CH3 (IIb)R═CH2CH3 Wherein, (IIIc)R1═ClR2═H (IIId)R1═BrR2═H (IIIe)R1═FR2═H (IIIf)R1═NO2R2═H (IIIg)R1═ClR2═Cl (IIIh)R1═BrR2═Br

Abstract translation: 本发明涉及由式（I）表示的化合物，其是茶氨酸衍生物和羧酸香豆素衍生物的缩合产物，由式（II）和式（III）表示的化合物，它们都是中间体 的缩合产物，制备这些化合物的方法，包含该化合物的药物组合物及其在制备用于预防和治疗肿瘤，炎症，心血管疾病，免疫缺陷疾病等的药物中的用途。 其中，（Ia）R = CH 3 R 1 = H R 2 = H（Ib）R = CH 2 CH 3 R 1 = H R 2 = H（Ic）R = CH 2 CH 3 R 1 = Cl R 2 = H（Id）R = CH 2 CH 3 R 1 = （Ie）R = CH 2 CH 3 R 1 = R R 2 = H（If）R = CH 2 CH 3 R 1 = N 2 R 2 = H（Ig）R = CH 2 CH 3 R 1 = Cl R 2 = Cl（Ih）R = CH 2 CH 3 R 1 = R 2 R 2 = ）R = CH 2 CH 3 R 1 = NH 2 R 2 = H其中，（IIa）R = CH 3（IIb）R = CH 2 CH 3其中，（IIIc）R 1 = Cl R 2 = H（IIId）R 1 = Br R 2 = H（IIIe） R2 = H（IIIf）R1 = NO2 R2 = H（IIIg）R1 = Cl R2 = C1（IIIh）R1 = Br R2 = Br

公开(公告)号：US20140243934A1

公开(公告)日：2014-08-28

申请号：US14168795

申请日：2014-01-30

Applicant: IMMUNOLIGHT, LLC

Inventor： Tuan VO-DINH ,  Jonathan P. Scaffidi ,  Venkata Gopal Reddy Chada ,  Benoit Lauly ,  Yan Zhang ,  Molly K. Gregas ,  Ian Nicholas Stanton ,  Joshua T. Stecher ,  Michael J. Therien ,  Frederic A. Bourke, JR. ,  Harold Walder ,  Zak Fathi ,  Jennifer A. Ayres ,  Zhenyuan Zhang ,  Joseph H. Simmons ,  Stephen John Norton

IPC: A61N5/06

CPC classification number: A61N5/062 ,  A61B5/0059 ,  A61B5/0071 ,  A61B5/055 ,  A61B5/4848 ,  A61B6/481 ,  A61K41/0042 ,  A61K41/0052 ,  A61K41/0061 ,  A61K49/0039 ,  A61L2/0047 ,  A61L2/08 ,  A61L2202/21 ,  A61L2202/22 ,  A61M5/007 ,  A61N1/406 ,  A61N5/02 ,  A61N5/0601 ,  A61N5/0618 ,  A61N5/0622 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/063 ,  A61N2005/0656 ,  A61N2005/0659 ,  A61N2005/0662 ,  A61N2005/067 ,  A61N2005/1098

Abstract: Products, compositions, systems, and methods for modifying a target structure. The methods may be performed in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to activate a photoactivatable agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

Abstract translation: 用于修改目标结构的产品，组成，系统和方法。 所述方法可以以非侵入性方式进行，通过将具有金属壳的纳米颗粒放置在受试者的靶结构附近的表面的至少一部分上，并施加引发能量，从而产生作用或改变 目标结构直接或通过调制剂。 纳米颗粒在暴露于第一波长λ1时被配置为产生具有比第一波长λ1更高的能量的辐射的第二波长λ2。 所述方法还可以通过施加起始能量来直接地或经由能量调节剂，任选地在一种或多种等离子体激元活性剂的存在下活化可光活化剂，从而对目标结构产生影响或改变。 包含配制或配置的产品或组合的套件以及用于实施这些方法的系统。

公开(公告)号：US20140219925A1

公开(公告)日：2014-08-07

申请号：US14129164

申请日：2012-06-28

Applicant: Philippe Bertrand ,  Regis Delatouche ,  Valerie Heroguez ,  Floraine Collette ,  Marc Gregoire ,  Christophe Blanquart ,  Fabien Gueugnon

Inventor： Philippe Bertrand ,  Regis Delatouche ,  Valerie Heroguez ,  Floraine Collette ,  Marc Gregoire ,  Christophe Blanquart ,  Fabien Gueugnon

IPC: A61K47/48 ,  A61K49/00

CPC classification number: A61K47/58 ,  A61K47/60 ,  A61K47/6935 ,  A61K49/0039 ,  A61K49/0041 ,  A61K49/0054

Abstract: Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents.

Abstract translation: 新型聚合物纳米颗粒或颗粒以及其作为药物和/或诊断剂的用途。